PSNL Stock Overview
Develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Personalis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.28 |
| 52 Week High | US$7.20 |
| 52 Week Low | US$1.14 |
| Beta | 1.9 |
| 1 Month Change | -9.78% |
| 3 Month Change | -38.79% |
| 1 Year Change | 156.86% |
| 3 Year Change | -52.54% |
| 5 Year Change | -62.83% |
| Change since IPO | -88.50% |
Recent News & Updates
NeXT Personal Testing And Moderna Partnership Will Improve Cancer Care
Mar 30 Strategic partnerships and agreements are expected to drive significant revenue and market expansion, particularly in MRD testing and tumor profiling.What You Can Learn From Personalis, Inc.'s (NASDAQ:PSNL) P/S After Its 40% Share Price Crash
Mar 21
Personalis, Inc. (NASDAQ:PSNL) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 02Recent updates
NeXT Personal Testing And Moderna Partnership Will Improve Cancer Care
Mar 30 Strategic partnerships and agreements are expected to drive significant revenue and market expansion, particularly in MRD testing and tumor profiling.What You Can Learn From Personalis, Inc.'s (NASDAQ:PSNL) P/S After Its 40% Share Price Crash
Mar 21Personalis, Inc. (NASDAQ:PSNL) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 02Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 04Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 19The Proper Play On Personalis
Oct 28Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Sep 14A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Jul 25Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Apr 19Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Mar 02Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story
Dec 18Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
Dec 04Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely
Sep 04Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)
Apr 17The Prognosis For Personalis
Jun 16Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?
Jun 09Shareholder Returns
| PSNL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 5.3% | 1.0% | 5.4% |
| 1Y | 156.9% | -27.3% | 3.6% |
Return vs Industry: PSNL exceeded the US Life Sciences industry which returned -27.3% over the past year.
Return vs Market: PSNL exceeded the US Market which returned 3.6% over the past year.
Price Volatility
| PSNL volatility | |
|---|---|
| PSNL Average Weekly Movement | 14.0% |
| Life Sciences Industry Average Movement | 10.5% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: PSNL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PSNL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 229 | Chris Hall | www.personalis.com |
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.
Personalis, Inc. Fundamentals Summary
| PSNL fundamental statistics | |
|---|---|
| Market cap | US$289.06m |
| Earnings (TTM) | -US$81.28m |
| Revenue (TTM) | US$84.61m |
3.4x
P/S Ratio-3.6x
P/E RatioIs PSNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSNL income statement (TTM) | |
|---|---|
| Revenue | US$84.61m |
| Cost of Revenue | US$57.79m |
| Gross Profit | US$26.83m |
| Other Expenses | US$108.11m |
| Earnings | -US$81.28m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 31.70% |
| Net Profit Margin | -96.06% |
| Debt/Equity Ratio | 0.9% |
How did PSNL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 20:23 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Personalis, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |